Rapid coronavirus tests may miss four in 10 asymptomatic people, a major review has concluded.
Researchers who analysed 64 studies of the effectiveness of lateral flow devices found they failed to detect 42 per cent of cases who didn’t show signs of illness.
The Cochrane review found the tests, which give a result in 30 minutes, were much better at catching symptomatic cases (78 per cent).
The findings have caused concern among some scientists because it’s thought that at least half of Covid transmission comes from patients who seem well.
Children are even less likely to fall ill with coronavirus but can still act as spreaders of the disease.
Hundreds of thousands of lateral flow tests are being used every day on teachers and pupils in a bid to keep schools open and Covid-free. They are also deployed in hospitals, care homes and across businesses.
Co-author of the report, Professor Jon Deeks, a biostatistician at Birmingham University, said ministers may have rushed the tests out in schools ‘without any supporting real-world evidence’.
The review also found the lateral flow tests were prone to giving false positives, when a test says someone is infected but they aren’t
Dr Ann Van den Bruel, associate professor of primary care at KU Leuven in Belgium, and an author of the review, said: ‘The risk of the false positives in the screening setting is very high, and you may end up having the opposite effect of what you want to achieve and you may have to close more workplaces, more classes…’
The review found one of the kits being used in the UK failed to meet international standards set by the World Health Organization (WHO).

Rapid lateral flow Covid tests — in use in schools across the UK — could miss more than half the cases in a population of people without symptoms, a review has concluded. Pictured: A student takes a lateral flow test at Weaverham High School in Cheshire on March 9
The studies reviewed by researchers were mostly from Europe and the USA and looked at the accuracy of rapid antigen tests.
Only three of the 64 studies looked exclusively at people without symptoms.
The review found, on average, LFDs only correctly identified 58 per cent of those who were infected with Covid but did not have symptoms.
For comparison, they were accurate in identifying Covid in 78 per cent of those who had developed symptoms.
One of the poorest performing tests was made by US company Innova, which only spotted 58 per cent of symptomatic infections. That test is currently being used in Britain.
The WHO’s minimum standards for testing is 80 per cent correct detection in people who have Covid.
Writing in the review, the researchers said: ‘In a population of 1,000 people with symptoms where there are 50 people with Covid, we would expect that about 40 people would be correctly identified as having Covid by rapid tests, and between six and 12 cases of Covid would be missed.
‘Between five and nine positive test results would turn out to be false positives. The true number of cases of Covid is likely to be lower in mass testing of people without symptoms.
‘In a population of 10,000 people with no symptoms, where 50 people really had Covid, between 24 and 35 people would be correctly identified as having Covid, and between 15 and 26 cases would be missed.
‘We would expect the tests to return between 125 and 213 positive results and between 90 and 189 of those positive results would be false positives.’
Dr Jac Dinnes, an epidemiologist at the University of Birmingham and author of the review, said bluntly: ‘These tests do not appear to perform as well in people who don’t have symptoms of Covid.’
He added: ‘Our review shows that some antigen tests may be useful in healthcare settings where Covid is suspected in people with symptoms.
‘These tests do not appear to perform as well in people who don’t have symptoms of Covid.
‘Confirming a positive result from a rapid test with a RT-PCR test, particularly where cases of Covid are low, may help avoid unnecessary quarantine.
‘All antigen tests will miss some people with infection, so it is important to inform people who receive a negative test result that they may still be infected.
‘There is some emerging evidence that the accuracy of the test is affected by who is doing it.’
Professor Deeks added: ‘It is good to have found evidence that some test brands do meet the minimum ‘acceptable’ performance standards set by WHO for testing people with symptoms.
‘However, they represent only a very small proportion of the commercially available tests.
‘The situation is different for testing people without symptoms, particularly for the use of repeated rapid antigen tests to screen for SARS-CoV-2 infection in school pupils and staff, and hospital and care home workers.
‘We didn’t find any data or studies evaluating the accuracy of these tests when used in repeated screening of people with no known exposure to SARS-CoV-2.
‘These testing policies have been implemented without any supporting real-world evidence.’
The full cochrane report is published online.